^
    Back
    Association details:
    Biomarker:EGFR exon 19 deletion + MET amplification
    Cancer:Lung Adenocarcinoma
    Drug:erlotinib (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    JTO Clin Res Rep
    Title:

    Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer

    Published date:
    06/19/2020
    Excerpt:
    He was treated with oral erlotinib daily for 14 months before developing disease progression in his liver. Targeted biopsy revealed metastatic lung adenocarcinoma with EGFR-delL747_T751 (exon 19 deletion) and MET amplification (FoundationOne, Foundation Medicine).
    DOI:
    10.1016/j.jtocrr.2020.100071
    Test:
    FoundationOne® Liquid CDx